Emyria Ltd (ASX:EMD) managing director Michael Winlo joins Proactive to discuss the healthcare stock’s Pax Centre acquisition.
The move brings a top-tier clinical service — specialising in comprehensive psychological trauma care — into the EMD fold, expanding its capabilities as it develops a pipeline of MDMA-assisted therapies.
Winlo says the acquisition will be transformative, strengthening Emyria’s clinical service foundations as it builds a care-centric model for delivering mental health treatments.
“The acquisition also improves our ability to collect crucial clinical data that can help engage payers as well as drive further care model improvements and novel drug development,” he told the market this week.
Pax Centre director Dr Jon Laugharne added: "The prospects of integrating Emyria's data-driven research approach with our existing care models is incredibly exciting.”
“We believe that with Emyria’s support we have an opportunity to become a centre of excellence that only offers innovative and cost-effective treatments to patients but also helps train and support the next generation of specialists and therapists."
Contact DetailsProactive Investors
Jonathan Jackson
+61 413 713 744
